Quick Answer
CytoDyn Inc. reported Stockholders Equity of -$96.04 million for the year ending 2025.
- CytoDyn Inc. showed an increase of +17.7% in Stockholders Equity from 2024 to 2025.
- This data is from CytoDyn Inc.'s annual report (Form 10-K), filed with the SEC on July 25, 2025.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: $6.25 million | Q4 2016: $5.38 million | Q1 2017: $5.42 million | Q3 2017: -$8.36 million | Q4 2017: -$12.79 million | Q1 2018: -$7.59 million | Q3 2018: -$19.80 million | Q4 2018: -$8.06 million | Q1 2019: -$6.25 million | Q3 2019: -$6.79 million | Q4 2019: -$13.63 million | Q1 2020: -$4.38 million | Q3 2020: $2.77 million | Q4 2020: -$6.53 million | Q1 2021: -$15.80 million | Q3 2021: -$25.19 million | Q4 2021: -$12.70 million | Q1 2022: -$22.46 million | Q3 2022: -$94.31 million | Q4 2022: -$115.97 million | Q1 2023: -$107.01 million | Q3 2023: -$116.89 million | Q4 2023: -$114.38 million | Q1 2024: -$119.38 million | Q2 2024: -$116.76 million | Q3 2024: -$85.21 million | Q4 2024: -$89.39 million | Q1 2025: -$92.98 million | Q2 2025: -$96.04 million | Q3 2025: -$99.51 million | Q4 2025: -$119.75 million.
- Over the full 17 years of available data (2009 to 2025), CytoDyn Inc.'s Stockholders Equity has declined by 4,171.4%.
- Historical annual values: Fiscal year 2025: -$96.04 million | Fiscal year 2024: -$116.76 million | Fiscal year 2023: -$109.50 million | Fiscal year 2022: -$94.40 million | Fiscal year 2021: -$21.02 million | Fiscal year 2020: -$2.48 million | Fiscal year 2019: -$8.91 million | Fiscal year 2018: -$13.16 million | Fiscal year 2017: -$1.10 million | Fiscal year 2016: $10.21 million | Fiscal year 2015: -$10.69 million | Fiscal year 2014: $3.92 million | Fiscal year 2013: -$223.9 thousand | Fiscal year 2012: -$3.97 million | Fiscal year 2011: -$5.01 million | Fiscal year 2010: -$3.22 million | Fiscal year 2009: -$2.25 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: